Multicomponent therapeutics for networked systems

Therapeutic regimens that comprise more than one active ingredient are commonly used in clinical medicine. Despite this, most drug discovery efforts search for drugs that are composed of a single chemical entity. A focus in the early drug discovery process on identifying and optimizing the activity of combinations of molecules can result in the identification of more effective drug regimens. A systems perspective facilitates an understanding of the mechanism of action of such drug combinations.

[1]  XXI.—An Experimental Research on the Antagonism between the Actions of Physostigma and Atropia , 1871 .

[2]  T. Fraser,et al.  XXI.—An Experimental Research on the Antagonism between the Actions of Physostigma and Atropia , 1871, Transactions of the Royal Society of Edinburgh.

[3]  S. Loewe,et al.  Die quantitativen Probleme der Pharmakologie , 1928 .

[4]  C. I. Bliss.  THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .

[5]  S. Loewe.  The problem of synergism and antagonism of combined drugs. , 1953, Arzneimittel-Forschung.

[6]  Paul Talalay,et al.  Analysis of combined drug effects: a new look at a very old problem , 1983 .

[7]  G E Stein,et al.  Amoxicillin-potassium clavulanate, a beta-lactamase-resistant antibiotic combination. , 1984, Clinical pharmacy.

[8]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[9]  P. Deprez,et al.  PANCREATITIS INDUCED BY 5-AMINOSALICYLIC ACID , 1989, The Lancet.

[10]  J. Knoben,et al.  An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations. , 1990, American journal of hospital pharmacy.

[11]  S Foungbé,et al.  Study of Costus lucanusianus: plant juice, fraction combinations and pharmacologic estimation of natural product total activity. , 1991, Journal of ethnopharmacology.

[12]  L. Guarente.  Synthetic enhancement in gene interaction: a genetic tool come of age. , 1993, Trends in genetics : TIG.

[13]  S D Kemp,et al.  Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. , 1995, Science.

[14]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[15]  AZT plus 3TC produces best results to date. , 1995, Positively aware : the monthly journal of the Test Positive Aware Network.

[16]  F. Belardelli.  Role of interferons and other cytokines in the regulation of the immune response , 1995, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[17]  D M Turner,et al.  Natural product source material use in the pharmaceutical industry: the Glaxo experience. , 1996, Journal of ethnopharmacology.

[18]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[19]  Michael E. Johnson,et al.  Multiple Novel Inhibitors of the NorA Multidrug Transporter of Staphylococcus aureus , 1999, Antimicrobial Agents and Chemotherapy.

[20]  Promising New Drugs and Combinations. Fulfilling Our Pledge. , 1999, The oncologist.

[21]  R. Brent,et al.  Genomic Biology , 2000, Cell.

[22]  K. Lewis,et al.  Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R Yuan,et al.  Traditional Chinese medicine: an approach to scientific proof and clinical validation. , 2000, Pharmacology & therapeutics.

[24]  J. Kaplan.  Génomique et médecine: réflexions prospectives. De la génétique booléeene des lois de Mendel à une médecine moléculaire multifactorielle. , 2000 .

[25]  M. Marschall,et al.  Recombinant Green Fluorescent Protein-Expressing Human Cytomegalovirus as a Tool for Screening Antiviral Agents , 2000, Antimicrobial Agents and Chemotherapy.

[26]  B. Stockwell.  Chemical genetics: ligand-based discovery of gene function , 2000, Nature Reviews Genetics.

[27]  M. Kavuru,et al.  Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. , 2000, The Journal of allergy and clinical immunology.

[28]  Jean-Claude Kaplan,et al.  Genomics and medicine: an anticipation. From Boolean Mendelian genetics to multifactorial molecular medicine. , 2000, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[29]  B. Stockwell,et al.  Frontiers in chemical genetics. , 2000, Trends in biotechnology.

[30]  G. Church,et al.  Identifying regulatory networks by combinatorial analysis of promoter elements , 2001, Nature Genetics.

[31]  B. Garvik,et al.  Principles for the Buffering of Genetic Variation , 2001, Science.

[32]  J. Groten,et al.  Toxicology of simple and complex mixtures. , 2001, Trends in pharmacological sciences.

[33]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[34]  J. Hainsworth,et al.  Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience. , 2001, Seminars in oncology.

[35]  B G Schuster,et al.  A new integrated program for natural product development and the value of an ethnomedical approach. , 2001, Journal of alternative and complementary medicine.

[36]  Gary D Bader,et al.  Systematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants , 2001, Science.

[37]  E. Lander,et al.  On the allelic spectrum of human disease. , 2001, Trends in genetics : TIG.

[38]  T. Ideker,et al.  A new approach to decoding life: systems biology. , 2001, Annual review of genomics and human genetics.

[39]  H. Nelson,et al.  Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. , 2001, The Journal of allergy and clinical immunology.

[40]  J. Bramson,et al.  Role of dendritic cell-derived cytokines in immune regulation. , 2001, Current pharmaceutical design.

[41]  Eric K. Gupta,et al.  Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. , 2002, Heart disease.

[42]  Nicola J. Rinaldi,et al.  Transcriptional Regulatory Networks in Saccharomyces cerevisiae , 2002, Science.

[43]  Fabrice P Cordelières,et al.  The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. , 2002, Developmental cell.

[44]  G. Maga,et al.  Combinations against combinations: associations of anti-HIV 1 reverse transcriptase drugs challenged by constellations of drug resistance mutations. , 2002, Current drug metabolism.

[45]  R. Pirker.  Two- versus three-drug combinations in the chemotherapy of advanced non-small-cell lung cancer. , 2002, Lung cancer.

[46]  B. Stockwell.  Chemical Genetic Screening Approaches to Neurobiology , 2002, Neuron.

[47]  E. Gilles,et al.  Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors , 2002, Nature Biotechnology.

[48]  Michael Q. Zhang,et al.  Functional genomics as applied to mapping transcription regulatory networks. , 2002, Current opinion in microbiology.

[49]  H. Kitano.  Systems Biology: A Brief Overview , 2002, Science.

[50]  M. Curatolo,et al.  Drug combinations in pain treatment: a review of the published evidence and a method for finding the optimal combination. , 2002, Best practice & research. Clinical anaesthesiology.

[51]  B. Stockwell,et al.  Eliminating membrane depolarization caused by the Alzheimer peptide Abeta(1-42, aggr.). , 2002, Biochemical and biophysical research communications.

[52]  M. Daniš,et al.  The new drug combinations: their place in the treatment of uncomplicated Plasmodium falciparum malaria , 2003, Fundamental & clinical pharmacology.

[53]  A. Loktionov.  Common gene polymorphisms and nutrition: emerging links with pathogenesis of multifactorial chronic diseases (review). , 2003, The Journal of nutritional biochemistry.

[54]  J. Lehár,et al.  Systematic discovery of multicomponent therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[55]  R. Stupp,et al.  New drugs and combinations for malignant glioma. , 2003, Forum.

[56]  F. Mondimore,et al.  Drug combinations for mania. , 2003, The Journal of clinical psychiatry.

[57]  William C Hahn,et al.  Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. , 2003, Cancer cell.

[58]  C. Arteaga.  Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs? , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  The development of combination drugs for atherosclerosis , 2003, Current atherosclerosis reports.

[60]  M. Winston,et al.  New components of the honey bee (Apis mellifera L.) queen retinue pheromone , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[61]  M. McGovern,et al.  Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). , 2003, The American journal of cardiology.

[62]  A L Hopkins,et al.  Target analysis: a priori assessment of druggability. , 2003, Ernst Schering Research Foundation workshop.

[63]  B. Stockwell,et al.  Biological mechanism profiling using an annotated compound library. , 2003, Chemistry & biology.

[64]  N. Hayashi,et al.  Oviposition Stimulants for the Tropical Swallowtail Butterfly, Papilio polytes, Feeding on a Rutaceous Plant, Toddalia asiatica , 2003, Journal of Chemical Ecology.

[65]  Robert N. Hughes,et al.  Cancer: Principles and Practice of Oncology , 2005 .